Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells

IL-21 Stimulates Human Myeloma Cell Growth through an Autocrine IGF-1 Loop

(2014) E. Menoret et al.   JOURNAL OF IMMUNOLOGY

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells

(2012) David Chiron et al.   BLOOD CELLS MOLECULES AND DISEASES

CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells

(2012) D Kim et al.   LEUKEMIA

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

The peripheral CD138+ population but not the CD138− population contains myeloma clonogenic cells in plasma cell leukaemia patients

(2011) David Chiron et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma

(2011) P Moreau et al.   LEUKEMIA

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

(2011) B Paiva et al.   LEUKEMIA

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

(2010) T. Steinbrunn et al.   BLOOD

Novel therapeutic targets for multiple myeloma

(2010) Anuj Mahindra et al.   Future Oncology

CD117 expression in gammopathies is associated with an altered maturation of the myeloid and lymphoid hematopoietic cell compartments and favorable disease features

(2010) M. Schmidt-Hieber et al.   HAEMATOLOGICA

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines

(2010) J. Moreaux et al.   HAEMATOLOGICA

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

(2009) Anne Catherine Sprynski et al.   BLOOD

A humanised anti-IGF-1R monoclonal antibody (AVE1642) enhances Bortezomib-induced apoptosis in myeloma cells lacking CD45

(2009) G Descamps et al.   BRITISH JOURNAL OF CANCER

Genetic Subgrouping of Melanoma Reveals New Opportunities for Targeted Therapy

(2009) K. S.M. Smalley et al.   CANCER RESEARCH

Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody

(2009) N. Chapuis et al.   HAEMATOLOGICA

Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity

(2008) J. C. Montero et al.   HAEMATOLOGICA

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

(2008) Gema Mateo et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I, Pharmacokinetic and Pharmacodynamic Study of the Anti–Insulinlike Growth Factor Type 1 Receptor Monoclonal Antibody CP-751,871 in Patients With Multiple Myeloma

(2008) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis

(2007) Régis Bataille et al.   LEUKEMIA RESEARCH